Apr 25, 2013, 08.10 AM | Source: CNBC-TV18
VK Sharma, fundamental analyst, HDFC Securities, recommends buying IDBI Bank and Ranbaxy Laboratories.
VK Sharma (more)
Head Private Broking & Wealth Management, | Capital Expertise: F&O
Here is the edited transcript of his discussion with CNBC-TV-18
On IDBI Bank
It has seen a decent buildup of open interest of around 8 percent. In terms of price also, the stock went up by 2-2.5 percent. At Rs 86.50 it is well placed and the next resistance comes at around Rs 90. So considering the fact that 85 Call was the level at around Rs 2.2, one can buy that with a stop loss of Rs 1. Even if the stock touches the price of Rs 90, the target price of Rs 5 in the 85 Call would be achieved.
The stock has made a recent 9-week high. It closed at around Rs 456. The price went up by something like 2.5 percent. Even if one were to buy the 460 Call at around Rs 5.5 and keep a stop loss at Rs 2 it would be possible to earn a premium of Rs 7 on this. So the Call that one is buying at Rs 5.5, it would be possible to sell it around Rs 12 in a day or two itself.
IDBI Bank's Q3 results on February 12, 2016
IDBI Bank Ltd has informed BSE that a meeting of t
Go long in IDBI Bank; sell JSPL, Bata India: Chandan Taparia
Chandan Taparia of Anand Rathi Securities recommen
IDBI Bank to raise Rs 3,771 cr through QIP route
"Board of Directors of the bank has approved revis
IDBI Bank revises QIP issue
IDBI Bank Ltd has informed BSE that Board of Direc
IDBI appoints 7 i-bankers for nearly Rs 4,000-cr QIP issue
Without naming the i-bankers, IDBI Bank deputy man
Bullish on PSU banks, IDBI Bank may head higher: Niraj Dalal
Niraj Dalal, Independent Market Expert is bullish
27 PSU banks write off Rs 1.14 lakh cr bad debts during 2012-15
For the fiscal ended March 2015, public sector ban
HDFC Bank, City Union Bank best bets: Mehraboon Irani
Mehraboon Irani of Nirmal Bang Securities is of th